
Cellectar Biosciences Investor Relations Material
Latest events

Q1 2025
Cellectar Biosciences
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cellectar Biosciences Inc
Access all reports
Cellectar Biosciences Inc (CLRB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer. Leveraging its proprietary phospholipid drug conjugate (PDC) delivery platform, Cellectar aims to develop targeted therapies designed to enhance treatment outcomes by selectively delivering cancer-killing agents to tumor cells, minimizing the impact on normal tissues. The company is headquartered in Florham Park, New Jersey, and its shares are listed on the Nasdaq.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
CLRB
Country
🇺🇸 United States